Eli Lilly and Company
Eli Lilly
LLY · NYSE
Healthcare
Catalog as of September 15, 2026. Not a live market feed.
- Fiscal Year
- 2025
- Revenue
- $65.2B
- Assets
- $112.5B
- SEC filing
- DEF 14A
- Filed
- March 20, 2026
Executive Compensation
Compensation reported for Eli Lilly’s named executive officers, including salary, stock awards, incentive compensation, other compensation, and total compensation.
David A. Ricks
Chair, President, And Chief Executive Officer
$36.7M
Reported total
- Salary
- $1,700,000
- Stock awards
- $29,810,500
- Incentives
- $0
- Option awards
- $0
- Other
- $5,187,837
Daniel M. Skovronsky
M.D., Ph.d. Executive Vice President, Chief Scientific And Product Officer And President, Lilly Research Labs
$17.8M
Reported total
- Salary
- $1,490,385
- Stock awards
- $15,249,039
- Incentives
- $0
- Option awards
- $0
- Other
- $1,047,152
Anat Hakim
Executive Vice President, General Counsel And Secretary
$9.8M
Reported total
- Salary
- $1,000,000
- Stock awards
- $8,180,000
- Incentives
- $0
- Option awards
- $0
- Other
- $665,518
Lucas Montarce
Executive Vice President And Chief Financial Officer
$8.5M
Reported total
- Salary
- $1,000,000
- Stock awards
- $7,180,000
- Incentives
- $0
- Option awards
- $0
- Other
- $303,315
Jake Van Naarden
Executive Vice President And President, Lilly Oncology And Head Of Corporate Business Development
$7.6M
Reported total
- Salary
- $920,192
- Stock awards
- $6,506,019
- Incentives
- $0
- Option awards
- $0
- Other
- $159,886
David A. Ricks
Chair, President, And Chief Executive Officer
$36.7M
Reported total · FY2025 · SCT Total as filed
Source: DEF 14A Summary Compensation Table, filed March 20, 2026.
- Salary
- $1.7M
- Stock Awards
- $29.8M
- Other
- $5.2M
Historical Compensation
David A. Ricks total compensation, fiscal years 2023–2025.
| Fiscal Year | Salary | Stock Awards | Total Compensation |
|---|---|---|---|
| 2025 | $1,700,000 | $29,810,500 | $36,698,337 |
| 2024 | $1,690,385 | $25,454,373 | $29,242,926 |
| 2023 | $1,621,154 | $23,241,683 | $26,565,732 |
Named Executive Officers
David A. Ricks
Chair, President, And Chief Executive Officer
Eli Lilly · LLY
$36.7M
FY 2025 · DEF 14A
Lucas Montarce
Executive Vice President And Chief Financial Officer
Eli Lilly · LLY
$8.5M
FY 2025 · DEF 14A
Daniel M. Skovronsky
M.D., Ph.d. Executive Vice President, Chief Scientific And Product Officer And President, Lilly Research Labs
Eli Lilly · LLY
$17.8M
FY 2025 · DEF 14A
Anat Hakim
Executive Vice President, General Counsel And Secretary
Eli Lilly · LLY
$9.8M
FY 2025 · DEF 14A
Jake Van Naarden
Executive Vice President And President, Lilly Oncology And Head Of Corporate Business Development
Eli Lilly · LLY
$7.6M
FY 2025 · DEF 14A
Source information
- Company
- Eli Lilly and Company
- Ticker
- LLY · NYSE
- Filing type
- DEF 14A
- Fiscal year
- 2025
- Filing date
- March 20, 2026
- SEC accession number
- 0000059478-26-000029
Source: U.S. Securities and Exchange Commission, DEF 14A Summary Compensation Table. View SEC filing
Related Companies
Johnson & Johnson
JNJ · NYSE
Joaquin Duato
Chairman/CEO
$32.8M
FY 2025 reported total
View company →
UnitedHealth
UnitedHealth Group Incorporated
UNH · NYSE
Stephen Hemsley
Chief Executive Officer
$60.9M
FY 2025 reported total
View company →
AbbVie
AbbVie Inc.
ABBV · NYSE
Robert A. Michael
Chairman Of The Board And Chief Executive Officer
$32.5M
FY 2025 reported total
View company →
Abbott
Abbott Laboratories
ABT · NYSE
Robert B. Ford
Chairman Of The Board And Chief Executive Officer
$24.2M
FY 2025 reported total
View company →